Positive Association of US-FLI With the Severity of CAD
Launched by CHONGQING MEDICAL UNIVERSITY · Aug 2, 2024
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the connection between a specific measurement called the Ultrasonographic Fatty Liver Indicator (US-FLI) and the severity of coronary artery disease (CAD). CAD is a condition that affects the heart's blood vessels and can lead to serious heart problems. The researchers want to see if the level of fat in the liver, as indicated by US-FLI, can help predict how severe a patient’s coronary artery disease is. This study involves patients who are being evaluated for chest pain or related symptoms.
To participate in this trial, you need to be at least 18 years old and have undergone a heart examination at the hospital due to symptoms like chest pain. However, certain people cannot join, such as those with previous heart surgeries, incomplete medical records, or other specific health issues. If you qualify, you can expect to have your liver fat levels measured through an ultrasound, and this information will be used to understand the overall health of your heart. The study is currently recruiting participants from August 2022 to December 2023, and everyone is welcome to participate, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 18 years old
- • Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study
- Exclusion Criteria:
- • Incomplete clinical data
- • previous coronary stent implantation
- • no abdominal ultrasound examination
- • poor ultrasound image quality
- • congenital heart disease
- • tumor
- • thyroid diseases and infectious diseases
About Chongqing Medical University
Chongqing Medical University is a prestigious institution dedicated to advancing medical education, research, and healthcare innovation. As a leading clinical trial sponsor, the university is committed to conducting rigorous clinical research that adheres to the highest ethical standards and regulatory guidelines. With a strong focus on improving patient outcomes and contributing to scientific knowledge, Chongqing Medical University leverages its comprehensive resources, including a diverse faculty of experts and state-of-the-art facilities, to facilitate groundbreaking studies across various medical disciplines. Through its collaborative approach, the university aims to foster partnerships that enhance the translation of research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, Chongqing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported